Effects of anti-tumor necrosis factor α agents on bone

Current Opinion in Rheumatology

Volumn 24, Issue 5, 2012, Pages 576-585

  Kawai, Vivian K ^a   Stein, C Michael ^a   Perrien, Daniel S ^b   Griffin, Marie R ^a,c  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Anti TNF; bone loss; rheumatoid arthritis; spondyloarthropaties

Indexed keywords

ADALIMUMAB; BISPHOSPHONIC ACID DERIVATIVE; C REACTIVE PROTEIN; DISEASE MODIFYING ANTIRHEUMATIC DRUG; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INFLIXIMAB; METHOTREXATE; PLACEBO; PREDNISONE; TUMOR NECROSIS FACTOR ALPHA ANTIBODY;

ANTIINFLAMMATORY ACTIVITY; BONE DENSITY; BONE REMODELING; BONE TURNOVER; CYTOKINE RELEASE; DISEASE ACTIVITY; DISEASE CONTROL; DISEASE MARKER; DRUG EFFECT; FRACTURE; HUMAN; NONHUMAN; OSSIFICATION; OSTEOBLAST; OSTEOBLASTOGENESIS; OSTEOCLAST; OSTEOCLASTOGENESIS; OSTEOLYSIS; OSTEOPOROSIS; PRIORITY JOURNAL; REVIEW; RHEUMATOID ARTHRITIS; SAMPLE SIZE; SPONDYLOARTHROPATHY; TREATMENT OUTCOME;

ARTHRITIS, RHEUMATOID; BONE DISEASES; BONE REMODELING; HUMANS; OSTEOBLASTS; OSTEOCLASTS; SIGNAL TRANSDUCTION; SPONDYLARTHROPATHIES; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84864880343     PISSN: 10408711     EISSN: 15316963     Source Type: Journal    
DOI: 10.1097/BOR.0b013e328356d212     Document Type: Review

References (95)

1. Van Staa TP, Geusens P, Bijlsma JW, et al. Clinical assessment of the longterm risk of fracture in patients with rheumatoid arthritis. Arthritis Rheum 2006; 54:3104-3112.
2. Kim SY, Schneeweiss S, Liu J, et al. Risk of osteoporotic fracture in a large population-based cohort of patients with rheumatoid arthritis. Arthritis Res Ther 2010; 12:R154.
3. Haugeberg G, Uhlig T, Falch JA, et al. Bone mineral density and frequency of osteoporosis in female patients with rheumatoid arthritis: results from 394 patients in the Oslo County Rheumatoid Arthritis register. Arthritis Rheum 2000; 43:522-530.
4. Weiss RJ, Wick MC, Ackermann PW, Montgomery SM. Increased fracture risk in patients with rheumatic disorders and other inflammatory diseases: a case-control study with 53,108 patients with fracture. J Rheumatol 2010; 37:2247-2250.
5. Bernstein CN, Blanchard JF, Leslie W, et al. The incidence of fracture among patients with inflammatory bowel disease: a population-based cohort study. Ann Intern Med 2000; 133:795-799.
6. Cooper C, Coupland C, Mitchell M. Rheumatoid arthritis, corticosteroid therapy and hip fracture. Ann Rheum Dis 1995; 54:49-52.
7. Card T, West J, Hubbard R, Logan RF. Hip fractures in patients with inflammatory bowel disease and their relationship to corticosteroid use: a population based cohort study. Gut 2004; 53:251-255.
8. Keffer J, Probert L, Cazlaris H, et al. Transgenic mice expressing human tumour necrosis factor: a predictive genetic model of arthritis. EMBO J 1991; 10:4025-4031.
9. Lin CL, Moniz C, Chambers TJ, Chow JW. Colitis causes bone loss in rats through suppression of bone formation. Gastroenterology 1996; 111:1263-1271.
10. Gough AK, Lilley J, Eyre S, et al. Generalised bone loss in patients with early rheumatoid arthritis. Lancet 1994; 344:23-27.
11. Ding C, Parameswaran V, Udayan R, et al. Circulating levels of inflammatory markers predict change in bone mineral density and resorption in older adults: a longitudinal study. J Clin Endocrinol Metab 2008; 93:1952-1958.
12. Kobayashi K, Takahashi N, Jimi E, et al. Tumor necrosis factor alpha stimulates osteoclast differentiation by a mechanism independent of the ODF/RANKLRANK interaction. J Exp Med 2000; 191:275-286.
13. Boyce BF, Schwarz EM, Xing L. Osteoclast precursors: cytokine-stimulated immunomodulators of inflammatory bone disease. Curr Opin Rheumatol 2006; 18:427-432.
14. Pascher E, Perniok A, Becker A, Feldkamp J. Effect of 1alpha,25(OH)2-vitamin D3 on TNF alpha-mediated apoptosis of human primary osteoblastlike cells in vitro. Horm Metab Res 1999; 31:653-656.
15. Gilbert L, He X, Farmer P, et al. Inhibition of osteoblast differentiation by tumor necrosis factor-alpha. Endocrinology 2000; 141:3956-3964.
16. Yoshihara R, Shiozawa S, Imai Y, Fujita T. Tumor necrosis factor alpha and interferon gamma inhibit proliferation and alkaline phosphatase activity of human osteoblastic SaOS-2 cell line. Lymphokine Res 1990; 9:59-66.
17. Lee CK, Lee EY, Chung SM, et al. Effects of disease-modifying antirheumatic drugs and antiinflammatory cytokines on human osteoclastogenesis through interaction with receptor activator of nuclear factor kappaB, osteoprotegerin, and receptor activator of nuclear factor kappaB ligand. Arthritis Rheum 2004; 50:3831-3843.
18. Redlich K, Gortz B, Hayer S, et al. Repair of local bone erosions and reversal of systemic bone loss upon therapy with antitumor necrosis factor in combination with osteoprotegerin or parathyroid hormone in tumor necrosis factormediated arthritis. Am J Pathol 2004; 164:543-555.
19. Saito H, Kojima T, Takahashi M, et al. A tumor necrosis factor receptor loop peptide mimic inhibits bone destruction to the same extent as antitumor necrosis factor monoclonal antibody in murine collagen-induced arthritis. Arthritis Rheum 2007; 56:1164-1174.
20. D'Amelio P, Fornelli G, Roato I, Isaia GC. Interactions between the immune system and bone. World J Orthop 2011; 2:25-30.
21. Agrawal M, Arora S, Li J, et al. Bone, inflammation, and inflammatory bowel disease. Curr Osteoporos Rep 2011; 9:251-257.
22. Schett G, David JP. The multiple faces of autoimmune-mediated bone loss. Nat Rev Endocrinol 2010; 6:698-706.
23. Zaidi M. Skeletal remodeling in health and disease. Nat Med 2007; 13:791-801.
24. Teti A. Bone development: overview of bone cells and signaling. Curr Osteoporos Rep 2011; 9:264-273.
25. Redlich K, Smolen JS. Inflammatory bone loss: pathogenesis and therapeutic intervention. Nat Rev Drug Discov 2012; 11:234-250.
26. Ross FP. Osteoclast biology and bone resorption. In Rosen CJ, editor. Primer on the metabolic bone diseases and disorders of mineral metabolism. 7th ed. American Society for Bone and Mineral Research. Washington, D.C.: American Society for Bone and Mineral Research; 2009. pp.16-22.
27. Bonewald LF. Osteocytes. In Rosen CJ, editor. Primer on the metabolic bone diseases and disorders of mineral metabolism. 7th ed. American Society for Bone and Mineral Research. Washington, D.C.: American Society for Bone and Mineral Research; 2009. pp. 22-26.
28. Han Y, Cowin SC, Schaffler MB, Weinbaum S. Mechanotransduction and strain amplification in osteocyte cell processes. Proc Natl Acad Sci USA 2004; 101:16689-16694.
29. Li J, Rose E, Frances D, et al. Effect of oscillating fluid flow stimulation on osteocyte mRNA expression. J Biomech 2012; 45:247-251.
30. Rochefort GY, Pallu S, Benhamou CL. Osteocyte: the unrecognized side of bone tissue. Osteoporos Int 2010; 21:1457-1469.
31. Abe E, Ishimi Y, Takahashi N, et al. A differentiation-inducing factor produced by the osteoblastic cell line MC3T3-E1 stimulates bone resorption by promoting osteoclast formation. J Bone Miner Res 1988; 3:635-645.
32. Kodama H, Nose M, Niida S, Yamasaki A. Essential role of macrophage colony-stimulating factor in the osteoclast differentiation supported by stromal cells. J Exp Med 1991; 173:1291-1294.
33. Suda T, Tanaka S, Takahashi N. Macrophage colon-stimulating factor (M-CSF) is essential for differentiation rather than proliferation of osteoclast progenitors. Osteoporos Int 1993; 3 (Suppl 1):111-113.
34. Tanaka S, Takahashi N, Udagawa N, et al. Macrophage colony-stimulating factor is indispensable for both proliferation and differentiation of osteoclast progenitors. J Clin Invest 1993; 91:257-263.
35. Krum SA, Chang J, Miranda-Carboni G, Wang CY. Novel functions for NFkappaB: inhibition of bone formation.Nat Rev Rheumatol2010; 6:607-611.
36. Stein GS, Lian JB, van Wijnen AJ, et al. Runx2 control of organization, assembly and activity of the regulatory machinery for skeletal gene expression. Oncogene 2004; 23:4315-4329.
37. Zhao C, Irie N, Takada Y, et al. Bidirectional ephrinB2-EphB4 signaling controls bone homeostasis. Cell Metab 2006; 4:111-121.
38. Franceschi RT, Xiao G. Regulation of the osteoblast-specific transcription factor, Runx2: responsiveness to multiple signal transduction pathways. J Cell Biochem 2003; 88:446-454.
39. Ducy P, Zhang R, Geoffroy V, et al. Osf2/Cbfa1: a transcriptional activator of osteoblast differentiation. Cell 1997; 89:747-754.
40. Kruppa G, Thoma B, Machleidt T, et al. Inhibition of tumor necrosis factor (TNF)-mediated NF-kappa B activation by selective blockade of the human 55-kDa TNF receptor. J Immunol 1992; 148:3152-3157.
41. Lam J, Takeshita S, Barker JE, et al. TNF-alpha induces osteoclastogenesis by direct stimulation of macrophages exposed to permissive levels of RANK ligand. J Clin Invest 2000; 106:1481-1488.
42. Fuller K, Murphy C, Kirstein B, et al. TNFalpha potently activates osteoclasts, through a direct action independent of and strongly synergistic with RANKL. Endocrinology 2002; 143:1108-1118.
43. Komine M, Kukita A, Kukita T, et al. Tumor necrosis factor-alpha cooperates with receptor activator of nuclear factor kappaB ligand in generation of osteoclasts in stromal cell-depleted rat bone marrow cell culture. Bone 2001; 28:474-483.
44. Glantschnig H, Fisher JE, Wesolowski G, et al. M-CSF, TNFalpha and RANK ligand promote osteoclast survival by signaling through mTOR/S6 kinase. Cell Death Differ 2003; 10:1165-1177.
45. Redlich K, Hayer S, Ricci R, et al. Osteoclasts are essential for TNF-alphamediated joint destruction. J Clin Invest 2002; 110:1419-1427.
46. Abbas S, Zhang YH, Clohisy JC, Abu-Amer Y. Tumor necrosis factor-alpha inhibits preosteoblast differentiation through its type-1 receptor. Cytokine 2003; 22:33-41.
47. Gilbert LC, Rubin J, Nanes MS. The p55 TNF receptor mediates TNF inhibition of osteoblast differentiation independently of apoptosis. Am J Physiol Endocrinol Metab 2005; 288:E1011-E1018.
48. Kaneki H, Guo R, Chen D, et al. Tumor necrosis factor promotes Runx2 degradation through up-regulation of Smurf1 and Smurf2 in osteoblasts. J Biol Chem 2006; 281:4326-4333.
49. Mukai T, Otsuka F, Otani H, et al. TNF-alpha inhibits BMP-induced osteoblast differentiation through activating SAPK/JNK signaling. Biochem Biophys Res Commun 2007; 356:1004-1010.
50. Lee HL, Yi T, Woo KM, et al. Msx2 mediates the inhibitory action of TNF-alpha on osteoblast differentiation. Exp Mol Med 2010; 42:437-445.
51. Ochi H, Hara Y, Tagawa M, et al. The roles of TNFR1 in lipopolysaccharideinduced bone loss: dual effects of TNFR1 on bone metabolism via osteoclastogenesis and osteoblast survival. J Orthop Res 2010; 28:657-663.
52. Ghali O, Chauveau C, Hardouin P, et al. TNF-alpha's effects on proliferation and apoptosis in human mesenchymal stem cells depend on RUNX2 expression. J Bone Miner Res 2010; 25:1616-1626.
53. Wahl EC, Aronson J, Liu L, et al. Restoration of regenerative osteoblastogenesis in aged mice: modulation of TNF. J Bone Miner Res 2010; 25:114-123.
54. Gilbert L, He X, Farmer P, et al. Expression of the osteoblast differentiation factor RUNX2 (Cbfa1/AML3/Pebp2alpha A) is inhibited by tumor necrosis factor-alpha. J Biol Chem 2002; 277:2695-2701.
55. Lu X, Gilbert L, He X, et al. Transcriptional regulation of the osterix (Osx, Sp7) promoter by tumor necrosis factor identifies disparate effects of mitogenactivated protein kinase and NF kappa B pathways. J Biol Chem 2006; 281:6297-6306.
56. Diarra D, Stolina M, Polzer K, et al. Dickkopf-1 is a master regulator of joint remodeling. Nat Med 2007; 13:156-163.
57. Findlay DM, Atkins GJ. TWEAK and TNF regulation of sclerostin: a novel pathway for the regulation of bone remodelling. Adv Exp Med Biol 2011; 691:337-348.
58. van der Heijde D, Kavanaugh A, Gladman DD, et al. Infliximab inhibits progression of radiographic damage in patients with active psoriatic arthritis through one year of treatment: results from the induction and maintenance psoriatic arthritis clinical trial 2. Arthritis Rheum 2007; 56:2698-2707.
59. Lipsky PE, van der Heijde DM, St Clair EW, et al. Infliximab and methotrexate in the treatment of rheumatoid arthritis: anti-tumor necrosis factor trial in rheumatoid arthritis with Concomitant Therapy Study Group. N Engl J Med 2000; 343:1594-1602.
60. St Clair EW, van der Heijde DM, Smolen JS, et al. Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: a randomized, controlled trial. Arthritis Rheum 2004; 50:3432-3443.
61. van der Heijde D, Kivitz A, Schiff MH, et al. Efficacy and safety of adalimumab in patients with ankylosing spondylitis: results of a multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2006; 54:2136-2146.
62. Yasunori K, Masaaki T, Tetsuyuki N, et al. Reduction of urinary levels of pyridinoline and deoxypyridinoline and serum levels of soluble receptor activator of NF-kappaB ligand by etanercept in patients with rheumatoid arthritis. Clin Rheumatol 2008; 27:1093-1101.
63. Miheller P, Muzes G, Zagoni T, et al. Infliximab therapy improves the bone metabolism in fistulizing Crohn's disease. Dig Dis 2006; 24:201-206.
64. Abreu MT, Geller JL, Vasiliauskas EA, et al. Treatment with infliximab is associated with increased markers of bone formation in patients with Crohn's disease. J Clin Gastroenterol 2006; 40:55-63.
65. Barnabe C, Hanley DA. Effect of tumor necrosis factor alpha inhibition on bone density and turnover markers in patients with rheumatoid arthritis and spondyloarthropathy. Semin Arthritis Rheum 2009; 39:116-122.
66. Veerappan SG, O'Morain CA, Daly JS, Ryan BM. Review article: the effects of antitumour necrosis factor-alpha on bone metabolism in inflammatory bowel disease. Aliment Pharmacol Ther 2011; 33:1261-1272.
67. Lange U, Teichmann J, Muller-Ladner U, Strunk J. Increase in bone mineral density of patients with rheumatoid arthritis treated with anti-TNF-alpha antibody: a prospective open-label pilot study. Rheumatology (Oxford) 2005; 44:1546-1548.
68. Vis M, Voskuyl AE, Wolbink GJ, et al. Bone mineral density in patients with rheumatoid arthritis treated with infliximab. Ann Rheum Dis 2005; 64:336-337.
69. Vis M, Havaardsholm EA, Haugeberg G, et al. Evaluation of bone mineral density, bone metabolism, osteoprotegerin and receptor activator of the NFkappaB ligand serum levels during treatment with infliximab in patients with rheumatoid arthritis. Ann Rheum Dis 2006; 65:1495-1499.
70. Eekman DA, Vis M, Bultink IE, et al. Stable bone mineral density in lumbar spine and hip in contrast to bone loss in the hands during long-term treatment with infliximab in patients with rheumatoid arthritis. Ann Rheum Dis 2011; 70:389-390.
71. Kim SY, Schneeweiss S, Liu J, Solomon DH. Effects of disease-modifying antirheumatic drugs on nonvertebral fracture risk in rheumatoid arthritis: a population-based cohort study. J Bone Miner Res 2012; 27:789-796.
72. Chopin F, Garnero P, le Henanff A, et al. Long-term effects of infliximab on bone and cartilage turnover markers in patients with rheumatoid arthritis. Ann Rheum Dis 2008; 67:353-357.
73. Serelis J, Kontogianni MD, Katsiougiannis S, et al. Effect of anti-TNF treatment on body composition and serum adiponectin levels of women with rheumatoid arthritis. Clin Rheumatol 2008; 27:795-797.
74. Wijbrandts CA, Klaasen R, Dijkgraaf MG, et al. Bone mineral density in rheumatoid arthritis patients 1 year after adalimumab therapy: arrest of bone loss. Ann Rheum Dis 2009; 68:373-376.
75. Marotte H, Pallot-Prades B, Grange L, et al. A 1-year case-control study in patients with rheumatoid arthritis indicates prevention of loss of bone mineral density in both responders and nonresponders to infliximab. Arthritis Res Ther 2007; 9:R61.
76. Seriolo B, Paolino S, Sulli A, et al. Bone metabolism changes during anti-TNFalpha therapy in patients with active rheumatoid arthritis. Ann N Y Acad Sci 2006; 1069:420-427.
77. Haugeberg G, Conaghan PG, Quinn M, Emery P. Bone loss in patients with active early rheumatoid arthritis: infliximab and methotrexate compared with methotrexate treatment alone: explorative analysis from a 12-month randomised, double-blind, placebo-controlled study. Ann Rheum Dis 2009; 68:1898-1901.
78. Hoff M, Kvien TK, Kalvesten J, et al. Adalimumab therapy reduces hand bone loss in early rheumatoid arthritis: explorative analyses from the PREMIER study. Ann Rheum Dis 2009; 68:1171-1176.
79. Hoff M, Kvien TK, Kalvesten J, et al. Adalimumab reduces hand bone loss in rheumatoid arthritis independent of clinical response: subanalysis of the PREMIER study. BMC Musculoskelet Disord 2011; 12:54.
80. Guler-Yuksel M, Bijsterbosch J, Goekoop-Ruiterman YP, et al. Changes in bone mineral density in patients with recent onset, active rheumatoid arthritis. Ann Rheum Dis 2008; 67:823-828.
81. Guler-Yuksel M, Allaart CF, Goekoop-Ruiterman YP, et al. Changes in hand and generalised bone mineral density in patients with recent-onset rheumatoid arthritis. Ann Rheum Dis 2009; 68:330-336.
82. Dirven L, Guler-Yuksel M, de Beus WM, et al. Changes in hand bone mineral density and the association with the level of disease activity in patients with rheumatoid arthritis: bone mineral density measurements in a multicenter randomized clinical trial. Arthritis Care Res (Hoboken ) 2011; 63:1691-1699.
83. Allali F, Breban M, Porcher R, et al. Increase in bone mineral density of patients with spondyloarthropathy treated with antitumour necrosis factor alpha. Ann Rheum Dis 2003; 62:347-349.
84. Mauro M, Radovic V, Armstrong D. Improvement of lumbar bone mass after infliximab therapy in Crohn's disease patients. Can J Gastroenterol 2007; 21:637-642.
85. Pazianas M, Rhim AD, Weinberg AM, et al. The effect of anti-TNF-alpha therapy on spinal bone mineral density in patients with Crohn's disease. Ann N Y Acad Sci 2006; 1068:543-556.
86. Kang KY, Lee KY, Kwok SK, et al. The change of bone mineral density according to treatment agents in patients with ankylosing spondylitis. Joint Bone Spine 2011; 78:188-193.
87. Bernstein M, Irwin S, Greenberg GR. Maintenance infliximab treatment is associated with improved bone mineral density in Crohn's disease. Am J Gastroenterol 2005; 100:2031-2035.
88. Marzo-Ortega H, McGonagle D, Haugeberg G, et al. Bone mineral density improvement in spondyloarthropathy after treatment with etanercept. Ann Rheum Dis 2003; 62:1020-1021.
89. Briot K, Garnero P, le HA, et al. Body weight, body composition, and bone turnover changes in patients with spondyloarthropathy receiving antitumour necrosis factor {alpha} treatment. Ann Rheum Dis 2005; 64:1137-1140.
90. Briot K, Gossec L, Kolta S, et al. Prospective assessment of body weight, body composition, and bone density changes in patients with spondyloarthropathy receiving antitumor necrosis factor-alpha treatment. J Rheumatol 2008; 35:855-861.
91. Marzo-Ortega H, McGonagle D, Jarrett S, et al. Infliximab in combination with methotrexate in active ankylosing spondylitis: a clinical and imaging study. Ann Rheum Dis 2005; 64:1568-1575.
92. Visvanathan S, van der HD, Deodhar A, et al. Effects of infliximab on markers of inflammation and bone turnover and associations with bone mineral density in patients with ankylosing spondylitis. Ann Rheum Dis 2009; 68:175-182.
93. Harrison BJ, Hutchinson CE, Adams J, et al. Assessing periarticular bone mineral density in patients with early psoriatic arthritis or rheumatoid arthritis. Ann Rheum Dis 2002; 61:1007-1011.
94. Desai SP, Gravallese EM, Shadick NA, et al. Hand bone mineral density is associated with both total hip and lumbar spine bone mineral density in postmenopausalwomen with RA. Rheumatology (Oxford) 2010; 49:513-519.
95. Haugeberg G, Lodder MC, Lems WF, et al. Hand cortical bone mass and its associations with radiographic joint damage and fractures in 50-70 year old female patients with rheumatoid arthritis: cross sectional Oslo-Truro-Amsterdam (OSTRA) collaborative study. Ann Rheum Dis 2004; 63:1331-1334.